Welcome to our dedicated page for Bio-Rad Laboratories news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio-Rad Laboratories stock.
Bio-Rad Laboratories, Inc. (NYSE: BIO) is a global leader in providing innovative tools and services to the life science research and clinical diagnostics markets. Established in 1952 and headquartered in Hercules, California, Bio-Rad boasts a robust network of operations spanning the globe, supported by a dedicated team of over 7,600 employees.
Bio-Rad's core business is segmented into two main areas: Clinical Diagnostics and Life Sciences. In the Clinical Diagnostics segment, which contributes to 56% of the company’s sales, Bio-Rad offers a range of test systems and specialized quality controls designed to ensure the accuracy and reliability of clinical laboratory results. These products play a critical role in patient care, enabling healthcare providers to make informed decisions.
The Life Sciences segment, accounting for 44% of sales, focuses on developing and manufacturing instruments and reagents used in research, biopharmaceutical production, and food testing. Bio-Rad is also a market leader in digital PCR (dPCR) technology, which is pivotal in genomics, proteomics, and drug discovery research.
Bio-Rad serves over 100,000 research and industry customers worldwide, fostering significant advancements in scientific research and development. The company has built strong partnerships and customer relationships that drive the introduction of new technologies in fields such as genomics, proteomics, drug discovery, food safety, and medical diagnostics.
Geographically, Bio-Rad's revenue distribution is diversified with 42% of sales from the Americas, 31% from Europe, 31% from Asia, and 6% from other regions, highlighting its extensive global reach.
One notable aspect of Bio-Rad's portfolio is its 33% ownership in Sartorius, a leading supplier of laboratory and bioprocessing solutions. Sartorius specializes in single-use technology for biologics manufacturing, thereby complementing Bio-Rad's offerings and enhancing its presence in the biopharmaceutical market.
With a strong legacy of innovation and a commitment to advancing scientific and medical research, Bio-Rad continues to lead in delivering high-quality, reliable solutions to its customers.
Bio-Rad Laboratories reported Q4 2021 net sales of $732.8 million, down 7.2% year-over-year, with a gross margin of 54.7%. The Life Science segment saw a 23.8% sales decline primarily due to reduced COVID-19 demand, while Clinical Diagnostics rose by 12.6%. The company experienced a net loss of $1,573.7 million or $52.59 per diluted share, impacted by equity securities valuation changes. For full-year 2021, net sales increased 14.8% to $2.92 billion with a net income of $4.24 billion.
Bio-Rad Laboratories (NYSE: BIO, BIOb) has announced an in-person investor day in New York City on February 25, 2022, starting at 10:30 a.m. EST. The event will include presentations from CEO Norman Schwartz and the executive leadership team, followed by a Q&A session. A live webcast will be available, with registration required for attendance. A replay and the presentation slides will be accessible on Bio-Rad's website for a year. The company, a leader in life science research and clinical diagnostics, reported revenues exceeding $2.5 billion in 2020.
Bio-Rad Laboratories, Inc. (NYSE: BIO) will report its financial results for Q4 and full year 2021 on February 10, 2022, after market close. The company will host a conference call at 3 PM PT (6 PM ET) to discuss the results. Investors can listen by calling in or via a live webcast. Bio-Rad is a leader in life science research and clinical diagnostics, with 2020 revenues exceeding $2.5 billion.
Bio-Rad Laboratories, a leader in life science research and clinical diagnostics, will participate in a virtual Fireside Chat at the 40th Annual J.P. Morgan Healthcare Conference on January 11 at 1:30 PM PST. Key executives, including President and CEO Norman Schwartz, will present insights during the event. The live webcast can be accessed via the Bio-Rad Investor Relations website. Founded in 1952 and based in Hercules, California, Bio-Rad reported revenues exceeding $2.5 billion in 2020, serving a diverse clientele in various markets.
Bio-Rad Laboratories, Inc. (NYSE: BIO, BIO.B) has appointed Simon May as Executive Vice President and President of the Life Science Group, effective January 4, 2022. He takes over from Annette Tumolo, who will retire at that time. Dr. May previously led the Digital Biology Group, overseeing significant growth and acquisitions. His extensive experience in commercial operations makes him well-suited for this role. Bio-Rad, based in Hercules, California, achieved revenues exceeding $2.5 billion in 2020.
BioGX announced that its SARS-CoV-2 diagnostic portfolio can detect the Omicron variant (B.1.1.529). The surveillance program includes in-silico analyses confirming detection across all variants of interest. BioGX's COVID-19 RT-PCR tests are compatible with several real-time PCR platforms, notably the Xfree COVID-19 Direct RT-PCR, which is FDA authorized for multiple specimen types. This test offers extraction-free options, enhancing workflow efficiency. BioGX operates under ISO 13485 standards, providing over 60 multiplex real-time PCR products worldwide.
Bio-Rad Laboratories reported third-quarter 2021 net sales of $747.0 million, a 15.4% increase from $647.3 million year-over-year. The gross margin improved to 58.6% from 56.7% in Q3 2020. The Life Science segment sales rose 15.3% to $373.5 million, while Clinical Diagnostics saw a 15.5% increase to $372.2 million. Net income surged to $3,928.0 million or $129.96 per diluted share, compared to $1,314.8 million or $43.64 in the prior year. The company updated its 2021 guidance, now expecting 12-13% currency-neutral revenue growth.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) will report its financial results for Q3 2021 on October 28, 2021, after market close. A conference call will follow at 2 PM PT to discuss the results. Interested parties can listen by calling 844-200-6205 in the U.S. or 929-526-1599 internationally, using access code: 535686. The results and further details can be accessed on the company’s website. Bio-Rad, established in 1952, exceeded $2.5 billion in revenue in 2020 and operates worldwide with approximately 7,800 employees.
Bio-Rad Laboratories (NYSE: BIO) announced participation in a Fireside Chat at the 2021 Virtual Wells Fargo Healthcare Conference on September 9 at 11:40 AM (Pacific Time). Interested parties can access the live webcast via the Investor Relations section of bio-rad.com. Bio-Rad, a leader in life science research and clinical diagnostics, reported over $2.5 billion in revenue in 2020 and has been operational since 1952. Headquartered in
Bio-Rad Laboratories reported strong Q2 2021 financial results, with net sales of $715.9 million, up 33.4% from Q2 2020. The Life Science segment sales rose 32.6% to $334.2 million, while Clinical Diagnostics grew 34.3% to $380.2 million. Gross margin improved to 56.1% from 54.6% a year earlier. Net income was $914.1 million, or $30.32 per share, impacted by equity security valuations. The company updated its 2021 outlook, forecasting 10.0% to 10.5% non-GAAP currency-neutral revenue growth.
FAQ
What is the current stock price of Bio-Rad Laboratories (BIO)?
What is the market cap of Bio-Rad Laboratories (BIO)?
What does Bio-Rad Laboratories, Inc. specialize in?
When was Bio-Rad Laboratories founded?
Where is Bio-Rad Laboratories headquartered?
What are the core business segments of Bio-Rad?
What percentage of Bio-Rad's sales come from the Clinical Diagnostics segment?
How many employees does Bio-Rad have?
What is Bio-Rad's involvement in the biopharmaceutical industry?
What is Bio-Rad's market reach?
What is the significance of Bio-Rad's ownership in Sartorius?
How does Bio-Rad contribute to scientific research and development?
